Coccidioidomycosis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Coccidioidomycosis Market Outlook

Thelansis’s “Coccidioidomycosis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Coccidioidomycosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Coccidioidomycosis Overview

Coccidioidomycosis, also known as San Joaquin Valley fever, is a fungal infection caused by the fungi Coccidioides immitis and C. posadasii. It is typically transmitted through inhalation of airborne arthroconidia deposit into terminal bronchioles and enlarge to form spherules. Later, the spherules rupture, releasing new endospores and enabling the fungal life cycle. It can also disseminate to other body parts, including the bones, brain, skin, and lymphatic system. The symptoms of primary coccidioidal pneumonia often include cough, fever, and chest pain. Without further testing, it can be difficult to distinguish from other types of pneumonia, and the diagnosis may not be immediately considered in areas where the infection is common. Physical signs of the infection may be absent or limited to certain sounds when the chest is listened to with a stethoscope, and certain areas may be dull to touch. Progressive Coccidioidomycosis is uncommon in healthy individuals but more likely to occur in people with HIV, those using an immunosuppressant medication, those of advanced age, those in the second half of pregnancy or postpartum, and specific ethnic backgrounds (Filipino, African American, Native American, Hispanic, and Asian, in decreasing order of relative risk).

• The annual incidence of Coccidioidomycosis in the United States is estimated to be 42.6 cases per 100,000 population.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: